NU7441 (KU-57788) DNA-PK Inhibitor: Mechanism & Research Utility

Executive Summary: NU7441 (KU-57788) is a potent, ATP-competitive inhibitor of DNA-dependent protein kinase with an IC50 of approximately 13–14 nM and a Ki of 0.65 nM, showing minimal cross-reactivity with ATM and ATR even at concentrations up to 100 μM (product information). The compound is insoluble in ethanol or water but dissolves at ≥4.13 mg/mL in DMSO, making it suitable for in vitro and in vivo protocols. NU7441 is widely adopted for DNA repair research and oncology applications, notably sensitizing tumor cells to agents like etoposide and modulating cell cycle distribution. The product is distributed by APExBIO and is typically stored at -20°C, with working solutions recommended for immediate use. This article clarifies the molecular rationale, validated benchmarks, and workflow integration for NU7441, expanding on prior reports (extended mechanistic review).

Biological Rationale

DNA double-strand breaks (DSBs) are critical lesions that threaten genome stability. DNA-PK (DNA-dependent protein kinase), a serine/threonine kinase, is a core component of the non-homologous end joining (NHEJ) pathway, which repairs DSBs in mammalian cells. Inhibiting DNA-PK disrupts DSB repair, thereby sensitizing cells to cytotoxic DNA damage. This is especially relevant in cancer research, where resistance to radiotherapy and chemotherapeutic agents is often mediated by upregulated DNA repair pathways. Studies have shown that HIV-1 infection and latency impair DNA damage response in pericytes, with DNA-PK activity being a crucial mediator of cellular survival following genotoxic stress (J Neurovirol, 2019). Thus, selective DNA-PK inhibitors like NU7441 provide a targeted approach to dissecting and modulating DNA repair and cell fate decisions in oncology and neurovirology models.

Mechanism of Action of NU7441 (KU-57788) DNA-PK inhibitor

NU7441 (KU-57788) is a small-molecule, ATP-competitive inhibitor of DNA-PK. It binds to the kinase's ATP-binding site, thereby blocking phosphorylation events required for the NHEJ repair process. NU7441 exhibits an IC50 of 13–14 nM and a Ki of 0.65 nM for DNA-PK, reflecting high-affinity interaction (product information). Notably, it demonstrates minimal inhibition of related phosphatidylinositol 3-kinase–like kinases (PIKKs), such as ATM and ATR, even at concentrations up to 100 μM. Its inhibition of mTOR and PI3K is comparatively weak, with IC50 values of 1.7 μM and 5 μM, respectively. This selectivity profile allows researchers to interrogate DNA-PK–dependent processes without substantial off-target effects. Upon treatment, NU7441 leads to persistent DNA damage signals (e.g., increased γH2AX foci) and can provoke cell cycle arrest, particularly an increase in G1 phase at the expense of S phase in p53 wild-type cells (cell cycle review).

Evidence & Benchmarks

• NU7441 inhibits DNA-PK with an IC50 of 13–14 nM and Ki of 0.65 nM, showing high selectivity over ATM and ATR, which are not inhibited even at 100 μM (product data).
• NU7441 is insoluble in ethanol and water, but dissolves at ≥4.13 mg/mL in DMSO, facilitating stock preparation for cell-based assays (solubility information).
• In vitro, 1 μM NU7441 for 16 hours increases the G1 population and decreases S phase in HeLa and p53 wild-type cell lines, indicating cell cycle arrest (workflow guidance).
• NU7441 enhances the cytotoxicity of DNA damaging agents such as etoposide, leading to tumor growth delay in SW620 xenograft mouse models when administered at 10 mg/kg i.p. (preclinical efficacy).
• DNA-PK inhibition in HIV-infected pericytes reduces the cell population in response to DNA damage, supporting the key role of DNA-PK in DNA damage response (J Neurovirol, 2019).

This article clarifies benchmark selectivity data and protocol nuances, expanding on prior reviews such as the strategic oncology workflow guide, which focuses on translational and therapeutic perspectives.

Applications, Limits & Misconceptions

NU7441 is primarily applied in DNA repair research and oncology studies to dissect DNA-PK–mediated processes. It is a preferred tool for cell cycle arrest assays, DNA damage response pathway analysis, and combinatorial cytotoxicity protocols. However, its use in non-cancer models should be justified by explicit DNA-PK involvement. While effective in enhancing sensitivity to DNA damaging agents in various tumor cell lines, its impact in non-dividing or DNA repair–deficient cells may be limited. The compound is not recommended for chronic in vivo dosing without additional toxicology data, and its solubility constraints must be addressed during formulation. For an in-depth protocol comparison, see the scenario-driven laboratory guide, which addresses reproducibility and troubleshooting in cell viability assays.

Common Pitfalls or Misconceptions

• NU7441 is not a pan-PI3K inhibitor; it exhibits >100-fold selectivity for DNA-PK over mTOR and PI3K. Use in PI3K-dominated pathways is not advised unless DNA-PK involvement is established.
• It does not effectively inhibit ATM or ATR at concentrations up to 100 μM. Interpretation of results as ATM/ATR inhibition is incorrect.
• The compound is insoluble in water or ethanol; inappropriate solvent use results in precipitation and unreliable dosing.
• Long-term storage of NU7441 solutions is discouraged due to potential degradation; fresh DMSO stocks are recommended for each experiment.
• NU7441 is not a direct cytotoxin; its efficacy depends on co-administration with DNA damaging agents or stressors.

Workflow Integration & Parameters

NU7441 (KU-57788) is integrated into DNA repair and oncology research workflows as follows:

Protocol Parameters

• In vitro application: 1 μM NU7441 for 16 hours; optimal for HeLa and p53 wild-type lines when analyzing cell cycle effects.
• In vivo studies: 10 mg/kg administered via intraperitoneal injection in xenograft mouse models; standard for tumor growth delay protocols.
• Solubility: Dissolve in DMSO at ≥4.13 mg/mL for stock solutions; avoid ethanol or water as solvents.
• Storage: Store dry powder at -20°C; minimize freeze-thaw cycles and avoid long-term storage of solutions.
• Combinatorial assays: Co-treat with DNA damaging agents (e.g., etoposide) to assess sensitization and DNA damage response.

For alternative workflow recommendations and troubleshooting, the scenario-driven guide extends use cases for APExBIO's A8315 kit in advanced cell cycle and DNA repair protocols.

Conclusion & Outlook

NU7441 (KU-57788) is a benchmark selective DNA-PK inhibitor enabling high-resolution dissection of DNA repair and cell cycle pathways in oncology and DNA repair research. By providing nanomolar potency with minimal off-target effects, it empowers mechanistic studies and therapeutic investigations where DNA-PK is implicated. APExBIO's validated A8315 product ensures reproducibility and experimental fidelity. Recent evidence from neurovirology models underscores the compound's broader relevance in studying DNA damage responses beyond oncology, as in HIV-1–infected pericytes (J Neurovirol, 2019). As research advances, NU7441 remains a cornerstone for elucidating DNA-PK function and its translational significance in disease models.